Sorianil(Roflumilast)
Therapeutic Group: Skin
Presentation
Sorianil™ 0.3% Cream: Each gram of cream contains Roflumilast USP 3 mg.
Description
Roflumilast and its active metabolite (Roflumilast N-oxide) are inhibitors of PDE4 enzyme. Roflumilast and Roflumilast N-oxide inhibition of PDE4 (a major cyclic 3', 5'-adenosine monophosphate or, cyclic AMP metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP, thus providing anti-inflammatory & immunomodulatory effects. The specific mechanism by which Roflumilast exerts its therapeutic action is not well-defined.
Indications
Sorianil is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.
Dosage & Administration
Apply to the affected areas once daily and rub it in completely. Hands should be washed after application, unless the cream is for treatment of the hands.
Precautions
For external use only. Avoid contact with eyes, mouth, and other mucous
Commercial Pack
Sorianil™ 0.3% Cream: Each tube contains 30 gm cream.